ERBB2 and cholangiocarcinoma: While ERBB2/HER2 aberrations are well-characterized in breast and gastric cancers, our findings highlight the prevalence and potential clinical relevance of ERBB2/HER2 alterations in underrepresented cancer types, such as salivary glands, uterine, and cholangiocarcinomas.